73,255,869 Shares in Bausch Health Cos Inc. $BHC Acquired by Paulson & CO. Inc.

Paulson & CO. Inc. bought a new position in Bausch Health Cos Inc. (NYSE:BHC) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 73,255,869 shares of the company’s stock, valued at approximately $361,151,000. Bausch Health Cos accounts for approximately 14.0% of Paulson & CO. Inc.’s portfolio, making the stock its 4th largest position. Paulson & CO. Inc. owned about 19.58% of Bausch Health Cos at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Tacita Capital Inc purchased a new position in shares of Bausch Health Cos during the 2nd quarter worth $29,000. Caption Management LLC boosted its holdings in shares of Bausch Health Cos by 101.1% during the fourth quarter. Caption Management LLC now owns 4,464 shares of the company’s stock worth $31,000 after purchasing an additional 405,789 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its position in shares of Bausch Health Cos by 12,589.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock valued at $34,000 after purchasing an additional 4,910 shares during the period. Northwestern Mutual Wealth Management Co. grew its position in shares of Bausch Health Cos by 6,661.2% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock valued at $35,000 after purchasing an additional 5,329 shares during the period. Finally, Russell Investments Group Ltd. increased its stake in Bausch Health Cos by 65.9% in the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock valued at $51,000 after purchasing an additional 3,106 shares during the last quarter. 78.65% of the stock is owned by hedge funds and other institutional investors.

Bausch Health Cos Stock Up 0.8%

Shares of NYSE BHC opened at $6.74 on Wednesday. Bausch Health Cos Inc. has a 52-week low of $4.33 and a 52-week high of $8.00. The firm has a fifty day moving average of $5.43 and a 200-day moving average of $5.48. The stock has a market capitalization of $2.52 billion, a PE ratio of -2.28 and a beta of 0.38. The company has a quick ratio of 1.08, a current ratio of 1.44 and a debt-to-equity ratio of 54.68.

Bausch Health Cos (NYSE:BHC) last issued its earnings results on Wednesday, July 29th. The company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.30. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%.The business had revenue of $2.83 billion for the quarter, compared to analyst estimates of $2.59 billion. On average, analysts anticipate that Bausch Health Cos Inc. will post 4.35 EPS for the current year.

Insider Buying and Selling

In other Bausch Health Cos news, insider Aimee J. Lenar sold 36,827 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $7.03, for a total transaction of $258,893.81. Following the completion of the sale, the insider directly owned 334,853 shares in the company, valued at $2,354,016.59. This represents a 9.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

BHC has been the topic of several recent analyst reports. Zacks Research upgraded Bausch Health Cos from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. Weiss Ratings upgraded Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, July 31st. Wall Street Zen raised shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 1st. Finally, Jefferies Financial Group upgraded shares of Bausch Health Cos to a “hold” rating in a report on Wednesday, July 22nd. Six analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Bausch Health Cos presently has an average rating of “Reduce” and a consensus price target of $8.00.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.